ForesightRx is the world's first living partnering intelligence platform for biopharma. We combine AI-powered asset matching with conference-sourced, boots-on-ground intelligence to connect pharma in-licensors with biotech out-licensors.

How is ForesightRx different from Evaluate or Inpart?

Unlike database-only platforms, ForesightRx combines real-time conference intelligence, AI-driven matching, and full deal facilitation including CDA management, introduction orchestration, and HEOR support — all powered by MarksMan Healthcare's decade of scientific expertise.

Who uses ForesightRx?

Pharma BD teams use ForesightRx to discover pre-qualified biotech assets matched to their BD thesis. Biotech companies use it to get positioned in front of the right pharma partners without expensive conference travel.

Does ForesightRx charge biotech companies?

ForesightRx operates on a success-based model for biotech. We invest our time and resources first. Biotech companies pay only when a deal happens. Our incentives are fully aligned with yours.

Case Studies

Proof in practice.

We don't sell potential — we point at what already shipped. Three engagements that show the same operating model across Pharma BD, cross-border sourcing, and emerging-biotech out-licensing.

For Pharma BD

EU commercialization-ready in-licensing shortlist

Deck-aligned deterministic scoring + live web enrichment

Confidential · European Specialty Pharma European Union · 25+ markets

The Problem

A European specialty pharma operating across 25+ EU markets needed a continuously refreshed shortlist of in-licensing-ready assets that fit their EU commercialization muscle. They did not need another sprawling database; they needed a deck-aligned, deterministically scored list with the payer story already pre-flagged.

Our Approach

01Encoded every selection rule from the client's corporate-development deck (therapeutic-area weighting, stage gates, EU-rights filters, fit-tier sub-buckets) into a deterministic scoring engine — same yardstick on every asset.
02Layered live web enrichment from Perplexity Sonar across every shortlisted asset to surface the latest stage, indication, MOA, and any post-deck news with full source citations.
03Pre-flagged EU JCA readiness on every in-scope oncology / ATMP asset, so the BD team could see the payer-path risk before opening diligence.
04Delivered as both a branded Excel export (monthly refresh) and a live workspace inside the ForesightRx platform for the client's BD team.

Outcome

BD now opens diligence only on assets that have already cleared the internal deck criteria and have a credible payer pathway. Wasted-meeting rate dropped materially within the first quarter of the engagement.

What was delivered

Deterministic scoring engine encoding 12 selection rules
Per-asset Perplexity enrichment with cited sources
Sub-bucket fit tiering (Tier 1 / Tier 2 / Watchlist)
EU-rights status & regulatory-readiness flags
Monthly branded Excel export
Live workspace for the BD team

For Pharma BD · Cross-border

China-origin pipeline into Western pharma

Living shortlist sourced from NMPA, ChinaBio floor, and WeChat signal channels

Confidential · US Specialty Pharma China → Western markets

The Problem

A US-based specialty pharma needed a continuous flow of China-origin differentiated assets — oncology, immunology, rare disease — that were available for Western rights and could survive payer scrutiny in EU and US markets. Off-the-shelf databases showed Chinese pipelines weeks (sometimes quarters) after the window closed.

Our Approach

01Built a living China-origin shortlist sourced from NMPA filings, ChinaBio Partnering Forum floor coverage, CPIC Shanghai, WeChat / vernacular signal channels, and direct BD relationships in Shanghai, Beijing, and Suzhou.
02Pre-screened every asset for EU rights availability, JCA readiness signal for in-scope indications, and US AMCP / payer-value plausibility — so the BD team only evaluates assets with a credible Western commercialization path.
03On-site BD at four China-focused conferences per year with structured one-on-one meeting facilitation and same-day flash reports.
04Cross-border BD network in Shanghai, Beijing, Suzhou, and Guangzhou — local-language fluency, not translated databases.

Outcome

The client now sees China-origin assets weeks before they surface in English-language databases — and only evaluates those with a credible Western payer pathway already pre-flagged.

What was delivered

Continuous China-origin asset shortlist, refreshed weekly
EU-rights availability flag on every asset
JCA readiness signal for in-scope EU indications
US AMCP / payer-value plausibility pre-read
WeChat & vernacular channel signal monitoring
On-site BD at ChinaBio and CPIC Shanghai

For Emerging Biotech

From "great science, no deal" to first BD term sheet

Out-licensing positioning + EU JCA pre-read + curated intros — success-only fee

Confidential — Oncology Biotech Series A · Phase 1b oncology

The Problem

A Series-A oncology biotech with a differentiated Phase 1b asset had been pitching pharma BD for nine months without traction. Pharma reviewers liked the science but kept asking the same two questions the company could not answer cleanly: where is the comparator story for EU JCA, and what does the US AMCP package look like at launch?

Our Approach

01Reframed the asset story into the Problem → Patient → Proof framework — the language pharma BD reviewers respond to.
02Built a structured EU JCA pre-read: PICO mapping, comparator landscape, ITC feasibility assessment, and a clinical / payer evidence-gap analysis.
03Sketched the US AMCP-format dossier outline + budget-impact narrative + likely payer objections and response strategy.
04Curated a 24-name pharma BD target list, ran personalized outreach, and facilitated NCD exchange and CDA orchestration for the four most engaged counterparties.

Outcome

From nine months of no traction to a first term sheet within six months of engagement. The biotech paid nothing until the deal moved — aligned incentives, demonstrated through outcome.

What was delivered

BD-ready non-confidential deck (Problem → Patient → Proof)
EU JCA / HTA pre-read with PICO + comparator landscape
US AMCP-format dossier outline + payer-objection map
24-name curated BD target list with rationale
Personalized outreach + CDA orchestration
Success-only fee — paid on signed term sheet

Your engagement is the next case study.

Pharma BD looking for cross-border deal flow. Biotech with a partnerable asset and no path to the right table. Tell us which one you are.

I'm Pharma BD I'm an Emerging Biotech